Xerostomia, also referred to as dry mouth is a condition that results in limited production of saliva or alteration in the saliva quality to keep the mouth wet. Most commonly this is caused during inflammatory autoimmune diseases, nervous-system related diseases including stress, depression, anxiety etc. and traumas.
MARKET DYNAMICS
The Xerostomia Therapeutics Market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of the associated diseases such as Sjogren's syndrome, increasing usage of prescription medications, rising geriatric population, increasing adoption of chemotherapy and radiotherapy in cancer treatment, and prevalence of diseases such as HIV, Diabetes etc. Nevertheless high cost of Xerostomia therapeutics and lack of awareness is expected to restrict the market growth during the forecast period.
MARKET SCOPE
The "Global Xerostomia Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Xerostomia Therapeutics market with detailed market segmentation by Product, Type, and geography. The global Xerostomia Therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Xerostomia Therapeutics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Xerostomia Therapeutics market is segmented on the basis of Product and Type. Based on Product the market is segmented into Salivary Stimulants, Salivary Substitutes and Dentifrices. Based on Type the market is segmented into OTC and Prescription.
(image)
REGIONAL FRAMEWORKThe report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Xerostomia Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Xerostomia Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Xerostomia Therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Xerostomia Therapeutics market in these regions.
(image)
MARKET PLAYERSThe reports cover key developments in the Xerostomia Therapeutics Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Xerostomia Therapeutics Market are anticipated to lucrative growth opportunities in the future with the rising demand for Xerostomia Therapeutics in the global market. Below mentioned is the list of few companies engaged in the Xerostomia Therapeutics market.
The report also includes the profiles of key Xerostomia Therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
-Acacia Pharma
-Pfizer, Inc.
-GlaxoSmithKline plc
-Church & Dwight Co., Inc.
-Lupin
-Sun Pharmaceutical Industries, Ltd.
-Hikma Pharmaceuticals PLC
-Pendopharm
-OraCoat
-Parnell Pharmaceuticals, Inc.
(image)